Oridonin improves the therapeutic effect of lentinan on lung cancer

Gui,Yun; Cheng,Jing; Chen,Zhiguo

doi:10.3892/etm.2021.10318

Oridonin improves the therapeutic effect of lentinan on lung cancer

Authors:
- Yun Gui
- Jing Cheng
- Zhiguo Chen
View Affiliations

Affiliations: Department of Stomatology, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Department of Thoracic Surgery, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: June 16, 2021 https://doi.org/10.3892/etm.2021.10318
Article Number: 886
Copyright: © Gui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oridonin, a compound from Rabdosia rubescens, has been shown to exhibit a potent ability to improve the antitumor effects of lentinan (LNT). In the present study, the effects of oridonin, LNT, and the combination of these treatments were assessed on the normal human fetal lung fibroblast cell line MRC‑5, as well as the non‑small cell lung cancer cell line A549. Next, their effects on metastasis and survival in vivo were assessed in a mouse model of lung cancer. The effects of the treatments on the mRNA and protein expression levels of several regulatory factors in A549 cells and lung tissues were determined using reverse transcription‑quantitative PCR and western blotting. The results showed that the viability of MRC‑5 and A549 cells were not affected by 0‑20 µg/ml oridonin; 0‑300 µg/ml LNT did not affect the viability of MRC‑5 cells, but 50‑400 µg/ml LNT reduced the viability of A549 cells. Thus, 20 µg/ml oridonin and 100 or 300 µg/ml LNT were used in the subsequent experiments. Treatment with oridonin and LNT, alone or combined, had no effect on MRC‑5 cell viability. Oridonin treatment had no effect on A549 cell viability; however, LNT suppressed A549 cell viability, and oridonin promoted the suppressive effects of LNT on A549 cells. In vivo analysis showed that oridonin alone had no effect on metastasis and survival, but LNT decreased metastasis and survival in mice. Oridonin augmented the effects of LNT against metastasis and further improved the survival rates of mice. In both A549 cells and lung tissues, LNT increased the mRNA and protein expression levels of caspase‑3, caspase‑8, caspase‑9, Bax, p53, p21 and inhibitor of nuclear factor‑κB (NF‑κB)‑α, and reduced the mRNA and protein expression levels of Bcl‑2 and NF‑κB. Oridonin augmented all the effects of LNT on expression of these proteins in the cells. Together, the results showed that oridonin enhanced the antitumor effects of LNT, and may thus serve as an adjuvant alongside LNT as a novel anticancer regimen for treatment of lung cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Liu H, Xiong Y, Wang H, Yang L, Wang C, Liu X, Wu Z, Li X, Ou L, Zhang R and Zhu X: Effects of water extract from epimedium on neuropeptide signaling in an ovariectomized osteoporosis rat model. J Ethnopharmacol. 221:126–136. 2018.PubMed/NCBI View Article : Google Scholar
3	Wang C, Chen G, Wong J, Liu H, Xong Y, Wang P, Yang L, Zhu X and Zhang Rl: Effect of herba epimedium extract on bone mineral density and microstructure in ovariectomised rat. J Pharm Biomed Sci. 6:275–278. 2016.
4	Zhang M, Zhang Y, Zhang L and Tian Q: Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Prog Mol Biol Transl Sci. 163:297–328. 2019.PubMed/NCBI View Article : Google Scholar
5	Tian Y, Yi W, Bai L, Zhang P, Si J, Hou X, Deng Y and Hou J: Lentinan in-situ coated tungsten oxide nanorods as a nanotherapeutic agent for low power density photothermal cancer therapy. Int J Biol Macromol. 137:904–911. 2019.PubMed/NCBI View Article : Google Scholar
6	Meng X, Liang H and Luo L: Antitumor polysaccharides from mushrooms: A review on the structural characteristics, antitumor mechanisms and immunomodulating activities. Carbohydr Res. 424:30–41. 2016.PubMed/NCBI View Article : Google Scholar
7	Kidd PM: The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 5:4–27. 2000.PubMed/NCBI
8	Xia S, Zhang X, Li C and Guan H: Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm J. 25:638–643. 2017.PubMed/NCBI View Article : Google Scholar
9	Gui Z, Luo F, Yang Y, Shen C, Li S and Xu J: Oridonin inhibition and miR200b-3p/ZEB1 axis in human pancreatic cancer. Int J Oncol. 50:111–120. 2017.PubMed/NCBI View Article : Google Scholar
10	Zhang W, Huang Q and Hua ZC: Oridonin: A promising anticancer drug from China. Front Biol. 5:540–545. 2010.
11	Wang ZN, Wo XD and Zhou YL: Molecule mechanisms of Oridonin on tumors chemoprevention and therapy. China Medical Herald. 28:14–16. 2008.(In Chinese).
12	Yang J, Jiang H, Wang C, Yang B, Zhao L, Hu D, Qiu G, Dong X and Xiao B: Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects. Biomed Pharmacother. 72:125–134. 2015.PubMed/NCBI View Article : Google Scholar
13	Xu T, Jin F, Wu K, Ye Z and Li N: Oridonin enhances in vitro anticancer effects of lentinan in SMMC-7721 human hepatoma cells through apoptotic genes. Exp Ther Med. 14:5129–5134. 2017.PubMed/NCBI View Article : Google Scholar
14	Sun Z, Han Q, Duan L, Yuan Q and Wang H: Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. Oncol Lett. 15:1999–2005. 2018.PubMed/NCBI View Article : Google Scholar
15	Wang H, Mo S, Yang L, Wang P, Sun K, Xiong Y, Liu H, Liu X, Wu Z, Ou L, et al: Effectiveness associated with different therapies for senile osteopo-rosis: A network Meta-analysis. J Tradit Chin Med. 40:17–27. 2020.PubMed/NCBI
16	Li R, Xiao C, Liu H, Huang Y, Dilger JP and Lin J: Effects of local anesthetics on breast cancer cell viability and migration. BMC Cancer. 18(666)2018.PubMed/NCBI View Article : Google Scholar
17	Li X, Peng B, Zhu X, Wang P, Xiong Y, Liu H, Sun K, Wang H, Ou L, Wu Z, et al: Changes in related circular RNAs following ERβ knockdown and the relationship to rBMSC osteogenesis. Biochem Biophys Res Commun. 493:100–107. 2017.PubMed/NCBI View Article : Google Scholar
18	Liu X, Liu H, Xiong Y, Yang L, Wang C, Zhang R and Zhu X: Postmenopausal osteoporosis is associated with the regulation of SP, CGRP, VIP, and NPY. Biomed Pharmacother. 104:742–750. 2018.PubMed/NCBI View Article : Google Scholar
19	Amikishieva AV, Ilnitskaya SI, Nikolin VP, Popova NA and Kaledin VI: Depressive-like psychoemotional state versus acute stresses enhances Lewis lung carcinoma metastasis in C57BL/6J mice. Exp Oncol. 33:222–225. 2011.PubMed/NCBI
20	Qian Y, Wang D, Fan M, Xu Y, Sun X and Wang J: Effects of intrinsic metal ions of lentinan with different molecular weights from Lentinus edodes on the antioxidant capacity and activity against proliferation of cancer cells. Int J Biol Macromol. 120:73–81. 2018.PubMed/NCBI View Article : Google Scholar
21	Wang XE, Wang YH, Zhou Q, Peng M, Zhang J, Chen M, Ma LJ and Xie GM: Immunomodulatory effect of lentinan on aberrant T subsets and cytokines profile in non-small cell lung cancer patients. Pathol Oncol Res. 26:499–505. 2020.PubMed/NCBI View Article : Google Scholar
22	Liu H, Dilger JP and Lin J: Effects of local anesthetics on cancer cells. Pharmacol Ther. 212(107558)2020.PubMed/NCBI View Article : Google Scholar
23	Li R, Liu H, Dilger JP and Lin J: Effect of propofol on breast cancer cell, the immune system, and patient outcome. BMC Anesthesiol. 18(77)2018.PubMed/NCBI View Article : Google Scholar
24	Li R, Huang Y, Liu H, Dilger JP and Lin J: Comparing volatile and intravenous anesthetics in a mouse model of breast cancer metastasis. Cancer Res. 78(2162)2018.
25	Liu H: A clinical mini-review: Clinical use of Local anesthetics in cancer surgeries. G Med Sci. 1:030–034. 2020.
26	Liu H, Dilger JP and Lin J: The role of transient receptor potential melastatin 7 (TRPM7) in cell viability: A potential target to suppress breast cancer cell cycle. Cancers (Basel). 12(131)2020.PubMed/NCBI View Article : Google Scholar
27	Van Opdenbosch N and Lamkanfi M: Caspases in cell death, inflammation, and disease. Immunity. 50:1352–1364. 2019.PubMed/NCBI View Article : Google Scholar
28	Liu W, Gu J, Qi J, Zeng XN, Ji J, Chen ZZ and Sun XL: Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome. J Cell Mol Med. 19:1949–1955. 2015.PubMed/NCBI View Article : Google Scholar
29	Bao L, Wang Y, Ma R, Ren X, Cheng R and B A: Apoptosis-inducing effects of lentinan on the proliferation of human bladder cancer T24 cells. Pak J Pharm Sci. 28:1595–1600. 2015.PubMed/NCBI
30	Siddiqui WA, Ahad A and Ahsan H: The mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update. Arch Toxicol. 89:289–317. 2015.PubMed/NCBI View Article : Google Scholar
31	Wawryk-Gawda E, Chylińska-Wrzos P, Lis-Sochocka M, Chłapek K, Bulak K, Jędrych M and Jodłowska-Jędrych B: P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 251:525–533. 2014.PubMed/NCBI View Article : Google Scholar
32	Wang X, Simpson ER and Brown KA: p53: Protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 75:5001–5007. 2015.PubMed/NCBI View Article : Google Scholar
33	DiDonato JA, Mercurio F and Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012.PubMed/NCBI View Article : Google Scholar
34	Liu H: A prospective for the potential effect of Local Anesthetics on Stem-Like cells in colon cancer. Biomed J Sci & Tech Res. 25:18927–18930. 2020.
35	Wu Z, Ou L, Wang C, Yang L, Wang P, Liu H, Xiong Y, Sun K, Zhang R and Zhu X: Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. Biomed Pharmacother. 94:1–9. 2017.PubMed/NCBI View Article : Google Scholar
36	Chen G, Wang C, Wang J, Yin S, Gao H, Xiang LU, Liu H, Xiong Y, Wang P, Zhu X, et al: Antiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/β-catenin pathway. Exp Ther Med. 12:279–287. 2016.PubMed/NCBI View Article : Google Scholar
37	Liu H, Xiong Y, Zhu X, Gao H, Yin S, Wang J, Chen G, Wang C, Xiang L, Wang P, et al: Icariin improves osteoporosis, inhibits the expression of PPAR_Υ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp Ther Med. 13:1360–1368. 2017.PubMed/NCBI View Article : Google Scholar
38	Xiang Y, Guo Z, Zhu P, Chen J and Huang Y: Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science. Cancer Med. 8:1958–1975. 2019.PubMed/NCBI View Article : Google Scholar
39	Liu H, Dilger JP and Lin J: Lidocaine suppresses viability and migration of human breast cancer cells: TRPM7 as a target for some breast cancer cell lines. Cancers (Basel). 13(234)2021.PubMed/NCBI View Article : Google Scholar